Pfizer Market Cap 2010-2025 | PFE

Pfizer market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of July 08, 2025 is $145.66B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $145.659B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $737.016B 56.52
Johnson & Johnson (JNJ) United States $374.842B 15.50
AbbVie (ABBV) United States $335.210B 18.48
Novo Nordisk (NVO) Denmark $310.943B 20.60
Novartis AG (NVS) Switzerland $257.040B 14.68
Roche Holding AG (RHHBY) Switzerland $255.691B 0.00
Merck (MRK) United States $204.323B 10.44
Sanofi (SNY) France $118.160B 11.64
Bayer (BAYRY) Germany $31.320B 6.38
Innoviva (INVA) United States $1.196B 12.54